Objective Breast cancer survivors live longer due to more advanced cancer treatments;
however, cardiovascular disease (CVD) is the leading non-cancer cause of death in breast …

Anthracycline drugs mainly include doxorubicin, epirubicin, pirarubicin, and aclamycin,
which are widely used to treat a variety of malignant tumors, such as breast cancer …

Simple Summary One of the oldest anticancer drugs in use is doxorubicin. It associates with
cardiotoxicity that until now remains unresolved. Diastolic cardiac dysfunction can be the first …

Background Cardiotoxicity as a result of anthracycline chemotherapy has been linked to
increased morbidity and mortality in breast cancer patients. There is a need for early …

Objectives Palpitations are common and have a negative impact on women's quality of life.
While evidence suggests that inflammatory mechanisms may play a role in the development …

Abstract Purpose of Review This study aims to review the challenges of treating AML in
older patients, the spectrum of genomic aberrancies in this cohort, and discuss treatment …

It was found that sulfanylethanoic and 3-sulfanylpropanoic acids are effective regulators of
molecular weight with chain transfer constants of 0.441 and 0.317, respectively, and show …

Objective: The present study aimed to evaluate the protective role of cilengitide (CGT), an
integrin αvβ3 and αvβ5 inhibitor, on doxorubicin (DOX)-induced myocardial fibrosis and …

Breast cancer (BC) is the most common malignant neoplasia in women and is responsible
for one in six deaths from cancer in the female population. Five years after diagnosis, BC …

Cardiovascular disease, specifically heart failure (HF), remains a significant concern in the
realm of healthcare, necessitating the development of new treatments and biomarkers. The …